公开(公告)号：US20220340670A1

公开(公告)日：2022-10-27

申请号：US17687971

申请日：2022-03-07

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US11406688B2

公开(公告)日：2022-08-09

申请号：US16947126

申请日：2020-07-20

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: C07H21/04 ,  A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  A61P19/02 ,  A61K39/395 ,  G01N33/68

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

公开(公告)号：US09649361B2

公开(公告)日：2017-05-16

申请号：US14942841

申请日：2015-11-16

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: A61K48/00 ,  A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  G01N33/68

CPC classification number: A61K38/2006 ,  A61K38/1709 ,  C07K14/545 ,  C07K16/245 ,  G01N33/6869 ,  Y10S514/825

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

公开(公告)号：US20150299329A1

公开(公告)日：2015-10-22

申请号：US14610456

申请日：2015-01-30

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Yves Levy ,  Monica Montes

IPC: C07K16/28 ,  C07K16/00 ,  C07K14/005

CPC classification number: C07K16/2878 ,  A61K39/00 ,  A61K39/385 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/005 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/77 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12N2760/16122 ,  C12N2770/24222 ,  C12N2770/24234 ,  G01N33/6863 ,  Y02A50/39 ,  Y02A50/464 ,  Y02A50/466

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Abstract translation: 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

公开(公告)号：US20150064205A1

公开(公告)日：2015-03-05

申请号：US14484599

申请日：2014-09-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Jacques F. Banchereau ,  Gerard Zurawski ,  Hideki Ueno ,  Ling Ni

IPC: C07K16/28 ,  A61K47/42 ,  A61K47/36

CPC classification number: C07K16/2851 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K39/39 ,  A61K47/36 ,  A61K47/42 ,  A61K2039/55572 ,  A61K2039/6056 ,  C07K2317/76 ,  C07K2319/035 ,  C12N2760/16134

Abstract: Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections.

Abstract translation: 本文公开了用于增强Th1 / Th17细胞应答和降低Th2细胞应答的组合物和方法。 在各种实施方案中，本发明描述了在含有Dectin-1的人树状细胞中激活人树突状细胞的活化和增强抗原特异性T细胞应答，所述树突细胞包含与一种或多种抗原融合的抗Dectin-1特异性抗体或其片段 。 还可以包括TLR2配体以增强T细胞反应的活化和增强。 此外，本发明还包括基于本文所述的用于治疗病原体感染的组合物的方法。

公开(公告)号：US20140227268A1

公开(公告)日：2014-08-14

申请号：US14254206

申请日：2014-04-16

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Sangkon Oh ,  Gerard Zurawski ,  Sandra Zurawski ,  Dapeng Li

IPC: C07K16/28 ,  C07K14/435 ,  C07K14/37 ,  C07K14/405 ,  C07K14/005 ,  C07K14/195

CPC classification number: A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/5154 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N5/0639 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  Y02A50/472

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

Abstract translation: 本发明包括用于制备和使用可以例如激活DC和其他细胞的抗DC-ASGPR抗体的组合物和方法。

公开(公告)号：US20130122049A1

公开(公告)日：2013-05-16

申请号：US13740984

申请日：2013-01-14

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Anna Karolina Palucka ,  Jacques F. Banchereau

IPC: A61K35/28

CPC classification number: A61K35/28 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/6043

Abstract: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.

Abstract translation: 本发明包括用于分离，纯化和制备用于生产定制的癌症疫苗的免疫原性抗原的组合物和方法，其包括与包含热休克癌细胞的抗原接触的树突状细胞。

公开(公告)号：US11267895B2

公开(公告)日：2022-03-08

申请号：US16946302

申请日：2020-06-15

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20210024641A1

公开(公告)日：2021-01-28

申请号：US16946302

申请日：2020-06-15

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10716832B2

公开(公告)日：2020-07-21

申请号：US15488764

申请日：2017-04-17

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: C07H21/04 ,  A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  G01N33/68

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.